Can you get Ozempic on medical aid in South Africa?

Why does the diagnosis decide the Ozempic medical aid answer?

Because schemes fund medicine by condition, not by molecule. Ozempic is SAHPRA-registered for type 2 diabetes, and diabetes sits on the Chronic Disease List of Prescribed Minimum Benefit conditions, which means schemes are legally obliged to fund appropriate treatment for it. Obesity is not on that list, so the same pen, requested for weight management, meets a scheme rule that says no.

Spotlight's 2026 reporting summarises the position: schemes must cover diabetes treatment by law but provide GLP-1 medicines only when clinical criteria are met, and cover for obesity is more limited still. Most schemes classify weight management medicine as an exclusion on every plan tier.

None of this says anything about whether treatment works. It is a funding line, drawn where the law stops compelling schemes to pay.

Is obesity a Prescribed Minimum Benefit condition?

No. The Prescribed Minimum Benefits are a statutory list of conditions every registered South African scheme must fund, whatever the plan, and obesity is not on it. Type 2 diabetes is, through the Chronic Disease List, which is why the same pen is funded for one diagnosis and declined for the other.

The list sits under the Medical Schemes Act and the Council for Medical Schemes, not under any individual scheme. Everything outside it falls to scheme rules, and those rules class weight management medicine as an exclusion on nearly every plan option, at every tier.

Medicine has moved faster than the list. Doctors manage obesity as a chronic condition, and South Africa's policy debate on funding its treatment is active, but adding a condition to the Prescribed Minimum Benefits is a regulatory process, not a scheme decision.

Which medical aids pay for Ozempic in South Africa?

For weight management: none of the major schemes on standard 2026 benefits. For type 2 diabetes: several, always with conditions. Published positions compare like this.

Treat the table as a snapshot of published 2026 positions. Benefit rules change every January and differ between plan options within one scheme, so the only answer that counts is the one your scheme gives in writing for your plan.

Does Discovery cover Ozempic for weight loss?

No. Discovery members using semaglutide for weight management pay out of pocket or through their Medical Savings Account. Members with a confirmed type 2 diabetes diagnosis may qualify for funding through the Chronic Illness Benefit, subject to authorisation, pathology and plan rules.

Discovery keeps signalling movement. In April 2026 group executive Hylton Kallner said the group is working toward a position where everyone who needs these medicines, beyond diabetes, can access them, and pointed to arriving generics as the thing that changes the economics. That is a direction of travel, not a benefit you can claim today.

One recurring confusion: Vitality is a rewards programme, not a medicine benefit. Points and status do not fund a weekly injection for any diagnosis.

How does the type 2 diabetes route work?

Four steps, all documented. First, a confirmed diagnosis with pathology: typically an HbA1c result over the scheme's threshold. Second, your doctor registers you on the scheme's chronic programme for diabetes. Third, the doctor submits a clinical motivation for semaglutide specifically, since most schemes fund cheaper diabetes medicines first and reserve GLP-1s for defined criteria. Fourth, the scheme issues an authorisation, usually reviewed annually.

Do not manufacture the route. Claiming diabetes benefits without a genuine diagnosis is fraud, schemes audit these claims, and a doctor cannot code a weight management consultation as diabetes to get funding. If your reason for treatment is weight, plan on self-funding under current rules, with costs broken down in what GLP-1 treatment costs in South Africa.

Does medical aid cover Wegovy for weight loss instead?

Generally no. Wegovy is the semaglutide brand SAHPRA registered for chronic weight management, so a request for it is at least on-label, but the barrier is the diagnosis rather than the brand. Obesity sits outside the Prescribed Minimum Benefits, and schemes decline Wegovy for weight loss on the same exclusion they apply to Ozempic.

The registration detail still matters, in the other direction. Ozempic is registered for type 2 diabetes, so asking a scheme to fund it for weight management is asking it to fund off-label use, which hands the scheme a second reason to say no. Wegovy removes that objection; the exclusion remains.

Registration, doses and trial results for the weight management brand are covered in Wegovy in South Africa. Which semaglutide option fits, if any of them do, is a clinical decision a doctor makes on assessment, separate from the funding question.

Do hospital plans, gap cover or health insurance pay for Ozempic?

No, as a rule. Hospital plans fund in-hospital events and exclude out-of-hospital chronic medicine, so a monthly pen falls outside them entirely. Gap cover tops up in-hospital shortfalls between what specialists charge and what schemes pay, and health insurance products run on defined benefit lists that leave weight management medicine out.

One nuance for hospital plan members with type 2 diabetes: Prescribed Minimum Benefits bind every registered scheme option, hospital plans included, so the condition itself must be treated. The scheme still chooses which medicines meet that duty, and most meet it with older diabetes medicines rather than a GLP-1.

Employer wellness programmes are the last place people look, and they occasionally subsidise structured weight management support or GP visits. The medicine itself almost never appears in their benefits.

In practice that leaves two funding routes when a scheme declines the medicine: your own budget, and on most plans your Medical Savings Account, covered next.

What can you still claim when the scheme says no?

More than most members realise. A Medical Savings Account holds your own ring-fenced money, and most schemes let you pay for self-funded medicine from it at the pharmacy till even after the benefit declines the claim. A handful of plans exclude weight management medicine even from savings, so ask your scheme how it processes the transaction before relying on it.

The clinical side is usually claimable in the ordinary way. Day-to-day benefits often pay for GP or telehealth consultations, and baseline blood tests from a pathology lab commonly go through savings or day-to-day benefits without argument, because the tests themselves are standard pathology. Our medical aid guide walks through checking both sides of your plan.

Budget the whole year, though. Savings spent on a monthly medicine are savings unavailable for dentistry, optometry and GP visits later, and once savings run out, mid-year claims that would have sailed through start bouncing back to you.

What does self-funding Ozempic cost?

Spotlight reported in February 2026 that a maintenance dose of semaglutide or tirzepatide for weight management generally costs between R3,000 and R6,000 a month, with starting doses costing less. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

The monthly figure follows the dose. Treatment starts at 0.25 mg for four weeks, then steps up in stages over months, and higher-dose pens cost more, so the monthly medicine cost usually climbs through the first half-year. The pen-by-pen breakdown, and what sets the underlying regulated price, is in how much Ozempic is in South Africa.

Budget the clinical side too: an initial assessment, follow-up reviews as the dose changes, and any baseline blood tests a doctor requests, all separate from the pen.

Competition may soften the numbers. SAHPRA approved Sun Pharma's generic semaglutide in July 2026, the first of a dozen generic applications the regulator has said it is reviewing, and generics typically enter below the originator's regulated price. The generic is registered for type 2 diabetes, the same indication as Ozempic itself.

Which documents make a claim or savings payment stick?

Three pieces of paper do the work. From the pharmacy: an itemised invoice, which by law must show the medicine's Single Exit Price and the dispensing fee as separate lines. Schemes process these cleanly; till slips without the split get bounced.

From the doctor: an invoice with practice number and the ICD-10 code for the condition managed in the consultation. A weight management consultation has its own legitimate codes; the consultation is claimable even when the medicine is not.

From the lab: the pathology invoice listing each test. Keep every decline letter too. If your clinical picture changes, or your scheme changes its rules in a January benefit cycle, a documented history restarts the conversation from evidence rather than from scratch.

Can a doctor motivate for Ozempic cover?

Yes. A doctor can submit a clinical motivation to your scheme, and for type 2 diabetes it is standard paperwork with a real approval path. For weight management the motivation runs into an exclusion written into scheme rules, and no letter overrides an exclusion, so approvals stay rare.

The diabetes version is structured. The doctor completes the scheme's chronic medicine application with the ICD-10 diagnosis code, attaches pathology such as HbA1c results, lists the treatments already tried and includes the medicine's NAPPI code, which the pharmacy can supply. Authorisation then follows the scheme's approved medicine list.

For weight management, a documented case still has uses. Some schemes assess individual applications as exceptions or run ex-gratia processes, and a BMI trend over time, related conditions such as high blood pressure or sleep apnoea with test results, and the outcomes of previous structured attempts give an application its best chance.

Any treating doctor can write it; the scheme reads the clinical record rather than the letterhead.

What should you ask your scheme before starting treatment?

Four questions, asked in writing and answered in writing, settle everything the general rules cannot. First: is semaglutide on my plan option's medicine list, and for which conditions? Second: if the benefit declines it, will the scheme process a savings-account payment at the pharmacy till? Third: which of my day-to-day benefits pay for GP or telehealth consultations and pathology tests? Fourth: what documentation does a claim need on my specific option?

Name your exact plan option in the query, because answers differ between options inside the same scheme, and a call-centre answer about the wrong tier is worse than no answer. Keep the written reply with your treatment records.

Re-ask in December. Schemes publish new benefit rules each January, and this class of medicine is where movement is most likely, so last year's no is not permanent information.

Will medical aids start paying for Ozempic for weight loss?

The pressure is building in that direction. Discovery has said publicly it wants wider access, obesity medicine is a live policy debate in South Africa, and the first generic semaglutide was approved by SAHPRA in 2026, which weakens the cost argument schemes lean on. Movement, when it comes, will show up in the January benefit announcements, so re-check your scheme's rules each new benefit year. Scheme positions on the tirzepatide side are tracked in does medical aid pay for Mounjaro.

Whatever a scheme decides, the clinical screen comes first. Semaglutide's common side effects are nausea, diarrhoea, constipation and vomiting, mostly during dose increases, and it is not used in pregnancy or by people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. Practical ways to handle the common effects are covered in managing GLP-1 side effects. A doctor works through that assessment before any treatment plan is confirmed, funded or not.

Frequently asked questions